MPP and Unitaid Intellectual Property Report on Long-Acting Technologies

A market of long-acting products in low- and middle-income countries will be more challenging than for conventional, medications. Intellectual property issues are also likely to be complex and require significant investments and technology transfer for generic manufacturers to enter the market.

Unitaid and the Medicines Patent Pool have worked together to develop a brief overview of the intellectual property status of long-acting drugs, formulation processes and delivery devices for major infectious diseases that are in pre-clinical or later stages of development as of October 2018.